{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:54:03Z","timestamp":1792554843269,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ctrv.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T17:31:39Z","timestamp":1478799099000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients"],"prefix":"10.1016","volume":"52","author":[{"given":"Lindsay","family":"Angus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Beije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2016.11.001_b0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/joim.12065","article-title":"Endocrine therapy: is the first generation of targeted drugs the last?","volume":"274","author":"Pritchard","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.ctrv.2016.11.001_b0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ctrv.2016.11.001_b0015","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1158\/1078-0432.CCR-04-2569","article-title":"A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer","volume":"11","author":"De Laurentiis","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2010.33.5232","article-title":"Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer","volume":"30","author":"Amir","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.001_b0025","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0030","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2016.11.001_b0035","doi-asserted-by":"crossref","first-page":"36863","DOI":"10.1074\/jbc.R100047200","article-title":"Nuclear receptor minireview series","volume":"276","author":"Olefsky","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2016.11.001_b0040","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1677\/ERC-07-0281","article-title":"Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor","volume":"15","author":"Kojetin","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2016.11.001_b0045","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00026.2006","article-title":"Estrogen receptors: how do they signal and what are their targets","volume":"87","author":"Heldring","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ctrv.2016.11.001_b0050","first-page":"1388","article-title":"Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein","volume":"10","author":"Weis","year":"1996","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ctrv.2016.11.001_b0055","first-page":"1244","article-title":"An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer","volume":"57","author":"Zhang","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0060","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0065","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2016.11.001_b0070","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","article-title":"Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts","volume":"4","author":"Li","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.ctrv.2016.11.001_b0075","first-page":"1408","article-title":"Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor","volume":"7","author":"Pakdel","year":"1993","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ctrv.2016.11.001_b0080","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1158\/1078-0432.CCR-15-0360","article-title":"Efficacy of SERD\/SERM hybrid-CDK4\/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer","volume":"21","author":"Wardell","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0085","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2016.11.001_b0090","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nmeth898","article-title":"BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions","volume":"3","author":"Diehl","year":"2006","journal-title":"Nat Methods"},{"key":"10.1016\/j.ctrv.2016.11.001_b0095","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","article-title":"Digital PCR","volume":"96","author":"Vogelstein","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2016.11.001_b0100","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"key":"10.1016\/j.ctrv.2016.11.001_b0105","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1373\/clinchem.2015.238717","article-title":"Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer","volume":"61","author":"Guttery","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.ctrv.2016.11.001_b0110","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.18632\/oncotarget.3041","article-title":"Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform","volume":"6","author":"Kidess","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.11.001_b0115","doi-asserted-by":"crossref","first-page":"e31597","DOI":"10.1371\/journal.pone.0031597","article-title":"Winnowing DNA for rare sequences: highly specific sequence and methylation based enrichment","volume":"7","author":"Thompson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2016.11.001_b0120","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2016.11.001_b0125","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2016.11.001_b0130","first-page":"349","article-title":"Estrogen receptor mutations in tamoxifen-resistant breast cancer","volume":"54","author":"Karnik","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jnci\/87.6.446","article-title":"Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer","volume":"87","author":"Roodi","year":"1995","journal-title":"J Natl Cancer Inst"},{"issue":"540\u201353","key":"10.1016\/j.ctrv.2016.11.001_b0140","first-page":"e2","article-title":"Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens","volume":"166","author":"Takeshita","year":"2015","journal-title":"Trans Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0145","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/1078-0432.CCR-15-1534","article-title":"Sensitive detection of mono- and polyclonal esr1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0150","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm.3886","article-title":"Subclonal diversification of primary breast cancer revealed by multiregion sequencing","volume":"21","author":"Yates","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2016.11.001_b0155","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/2159-8290.CD-13-1014","article-title":"Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA","volume":"4","author":"Haber","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2016.11.001_b0160","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.10175","article-title":"Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer","author":"Onstenk","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.11.001_b0165","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-15-0943","article-title":"ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients","volume":"22","author":"Chu","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0170","doi-asserted-by":"crossref","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2016.11.001_b0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.trecan.2015.11.003","article-title":"Cancer evolution and the limits of predictability in precision cancer medicine","volume":"2","author":"Lipinski","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctrv.2016.11.001_b0180","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1038\/ncomms11579","article-title":"Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant","volume":"7","author":"Spoerke","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2016.11.001_b0185","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","article-title":"Mutational processes molding the genomes of 21 breast cancers","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2016.11.001_b0190","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.001_b0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.11.001_b0200","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 Clinical Trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2016.11.001_b0205","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.ctrv.2016.11.001_b0210","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Overlies plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.11.001_b0220","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.1253533","article-title":"Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility","volume":"345","author":"Yu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2016.11.001_b0225","article-title":"Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts","author":"Shaw","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2016.11.001_b0235","doi-asserted-by":"crossref","first-page":"11383","DOI":"10.1038\/ncomms11383","article-title":"The topography of mutational processes in breast cancer genomes","volume":"7","author":"Morganella","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2016.11.001_b0240","doi-asserted-by":"crossref","first-page":"32504","DOI":"10.18632\/oncotarget.8839","article-title":"Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients","volume":"7","author":"Takeshita","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.11.001_b0245","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827b","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2016.11.001_b0250","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.molonc.2015.11.006","article-title":"Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample","volume":"10","author":"Rothwell","year":"2016","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2016.11.001_b0255","doi-asserted-by":"crossref","unstructured":"Van Dessel LF, Beije N, Helmijr J, Vitale S, Kraan J, Look MP, et al. Application of circulating tumor DNA in prospective clinical oncology trials: standardization of pre-analytical conditions. Mol Oncol, 2016, in press.","DOI":"10.1002\/1878-0261.12037"},{"key":"10.1016\/j.ctrv.2016.11.001_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2016.03.012","article-title":"Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and Cell Save blood collection tubes","author":"Kang","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ctrv.2016.11.001_b0265","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/bcr80","article-title":"Estrogen receptor transcription and transactivation: Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors","volume":"2","author":"Ruff","year":"2000","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.001_b0270","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1152\/physrev.2001.81.4.1535","article-title":"Mechanisms of estrogen action","volume":"81","author":"Nilsson","year":"2001","journal-title":"Physiol Rev"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T13:10:50Z","timestamp":1568553050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216301177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":53,"alternative-id":["S0305737216301177"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}